 | | Vol. 14.11 – 24 March, 2023 |
| |
|
|
| Researchers showed that RB1-loss/E2F activation sensitized cancer cells to ferroptosis by upregulating the expression of ACSL4 and enriching ACSL4-dependent arachidonic acid-containing phospholipids, which are key components of ferroptosis execution.
[Journal Of Clinical Investigation] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists observed that trophoblastic cell-surface antigen (Trop-2) could serve as a cell surface target for isolating circulating tumor cells, which may serve as a predictive biomarker for antibody drug conjugates.
[Clinical Cancer Research] |
|
|
|
| Investigators reported the development of a novel CD46-targeted alpha therapy based on the internalizing human monoclonal antibody, YS5.
[Journal Of Experimental & Clinical Cancer Research] |
|
|
|
| Scientists investigated the role of the novel insulin/insulin-like growth factor 1 (IGF1) signaling modulator inceptor in prostate cancer.
[Molecular Metabolism] |
|
|
|
| Researchers investigated the effect of direct mitochondria transplantation on cancer cell proliferation and chemotherapeutic sensitivity in prostate and ovarian cancer models, both in vitro and in vivo.
[Biomedicine & Pharmacotherapy] |
|
|
|
| Scientists demonstrated that 3T3-L1 adipocyte conditioned media could endow PC3 and DU145 prostate cancer cells with stemness properties, by stimulating their sphere formation ability and promoting CD133 and CD44 expression.
[Journal of Cell Communication and Signaling] |
|
|
|
| Scientists mapped the interaction domains within the androgen receptor (AR) and transmembrane 4 superfamily 3 (TM4SF3) and discovered that TM4SF3 also physically interacted with AR-V7, regulating its protein stability and the viability of castration-resistant prostate cancer cells expressing AR-V7.
[Endocrinology] |
|
|
|
| Researchers showed how hormone therapy affected CACNA1D expression and CaV1.3 function. Cells were treated with anti-androgen drug, Enzalutamide or androgen-removal from media, mimicking androgen-deprivation therapy.
[Scientific Reports] |
|
|
|
| Investigators synthesized a 99mTc-labeled probe and investigated its potential for SPECT imaging of prostate cancer.
[Nuclear Medicine And Biology] |
|
|
|
|
| The authors provide an overview of the current systemic treatments available for metastatic castration-resistant prostate cancer and review studies that investigate the optimal timing for the use of radium-22.
[Future Oncology] |
|
|
|
|
| The new Phase III clinical study, ARASTEP, would investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence.
[Bayer] |
|
|
|
| Dr. Ekta Khurana, an associate professor of physiology and biophysics at Weill Cornell Medicine, has received a 3-year, $1.2 million grant from the United States Department of Defense to investigate how prostate cancer cells evolve to become resistant to hormone-blocking therapy.
[Weill Cornell Medicine] |
|
|
|
|
| April 11 – 12, 2023
New York, New York, United States |
|
|
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | Newcastle University – Newcastle upon Tyne, England, United Kingdom |
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | University of Miami – Miami, Florida, United States |
|
|
|
| | The Henry Ford Health System – Detroit, Michigan, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
